Suppliers / Delpharm Meppel

Delpharm Meppel

Netherlands 112 employees Updated 9 July 2026

Delpharm Meppel is a finished-dose manufacturer based in Netherlands. It appears in 10 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with EDE (AE) and NPRA (MY). Its GMP standing is certified by MFDS (Korea), US FDA and EMA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 31 October 2024 as VAI.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
10
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 31 October 2024 VAI US FDA
  • 26 January 2022 VAI US FDA
  • 27 June 2014 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Meppel, United Arab Emirates Not on file
MEPPEL, Netherlands Not on file
Netherlands, Netherlands 3002808518

Filings and GMP by regulator

Regulator Filings GMP certificates
EDE (AE) 7 None
NPRA (MY) 3 None
MFDS (Korea) None 2
US FDA None 1
EMA None 1
ANVISA (Brazil) None 1

Comparing suppliers?

Choose your molecules and target markets. Delpharm Meppel comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 31 October 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates